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Intragraft expression of IL-lO messenger RNA A novel correlate of
renal allograft rejection. A major conceptual advance is the formulation
that type I cytokines (such as IL-2 and IFN-y) enhance cellular immunity
and are host-protective, and that type II cytokines (such as IL-4 and IL-b)
dampen cellular immunity and facilitate the progression of infection. We
have explored the intragraft expression of type I and type II cytokines
during human renal allograft rejection. RNA was isolated from 98
allograft biopsies, and reverse transcription-PCR was used to amplify and
identify intragraft expression of mRNA encoding IL-2, IFN-y, IL-4, or
IL-b. Intragraft expression of IL-7 mRNA and TGF-131 mRNA was also
investigated. Our investigation demonstrated that: (a) intragraft expres-
sion of IL-b mRNA and IL-2 mRNA are significant correlates of acute
rejection; (b) IL-4, IL-7, IFN-y and TGF-1 mRNA expression do not
correlate with acute rejection; and (c) IL-b does not prevent in vivo
expression of IFN-y, IL-2, IL-7, or TGF-13b. Our studies identify, for the
first time, a significant association between intragraft IL-lU mRNA
expression and acute rejection, and suggest that treatment strategies
capable of constraining IL-lU expression might be of value in the
prevention of acute rejection.
IL-b was originally identified as a secretory product of murine
CD4+ T helper type II clones that inhibits IFN-y production by
CD4+ T helper type I clones [1]. Human IL-b, cloned from a
cDNA librasy prepared from a tetanus toxin specific CD4+ T cell
clones [2], in vitro inhibits not only the synthesis of IFN-'y but also
that of IL-2, TNF-a, lymphotoxin and GM-CSF [2—6]. The
cytokine synthesis inhibitory activity of IL-b as well as its ability
to constrain APC function of monocytes and functional programs
of T cells have advanced the consideration that IL-b might
function as an immunosuppressive cytokine [7—9]. Additional data
that support an immunosuppressive role for IL-b include: (a) the
demonstration that intradermal injection of recombinant IL-b
facilitates induction of in vivo hapten-specific tolerance [10]; and
(b) the finding that administration of anti-interleukin-lO antibod-
ies accelerates rejection of allogenic skin grafts [11].
Renal allograft rejection is dependent upon the coordinated
activation of alloreactive T cells and APCs. A diverse assembly of
lymphocytes, including CD4+T cells, CD8+T cells, antibody-
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forming B cells and other proinflammatory leukocytes and cyto-
kines participate in the anti-allograft response [12—14]. Acute
rejection is the most common cause of allograft loss, and is a
major risk factor for chronic rejection, a poorly understood and
relentlessly progressive graft destructive process.
In light of the demonstrated immunosuppressive activity of
IL-lU, we hypothesized that intragraft expression of IL-lU would
be a negative correlate of acute rejection. We further anticipated,
based on IL-lU's ability to inhibit cytokine synthesis, that intra-
graft expression of IL-b would preclude the induced expression
of IFN-y and IL-2.
The testing of the above hypotheses by mRNA phenotyping of
RNA isolated from human renal allograft biopsies forms the basis
of this report.
Methods
Subjects
Ninety-eight renal allograft core tissue samples were obtained
from eighty-five patients who received their renal allografts at our
institutions [The New York Hospital, NYC, NY (N = 63), and
Hennepin County Medical Center, Minneapolis, MN (N = 22)].
The biopsies were performed to determine the basis for graft
dysfunction and the renal allograft recipients were managed with
an immunosuppressive regimen of antilymphocyte antibodies
and/or cyclosporine, prednisone and azothioprine.
Histopathological evaluation of renal allograft biopsy specimens
Acute rejection. The Banif working classification criteria [15]
were used to classify renal allograft histology. The histologic
diagnosis of acute rejection was based on the presence of signif-
icant interstitial infiltration by lymphocytes, and invasion of
tubules (tubulitis) and/or the walls of blood vessels (intimal
arteritis) [15].
Chronic allograft nephropathy. The histologic diagnosis was
based on the presence of interstitial fibrosis and tubular atrophy
[15]. The diagnosis was also based on the presence of arterial
fibrous intimal thickening, and morphologic changes consistent
with chronic transplant nephropathy [15].
CsA nephrotoxicity/acute tubular necrosis (A TN). The presence
of dilated tubular lumina with flattened, attenuated proximal
tubular epithelial cells and cell loss and necrosis were considered
as histologic features of ATN. Isometric vacuolization of tubules,
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Table 1. Sequences of oligonucleotide primers used in RT-PCR
IL-JO (PNAS 88.1172—1176, 1991)
5' sense
3' antisense
IL-2 (PNAS 80: 743 7—7441, 1983)
5' sense
3' antisense
IFN-y (Nature 298:859—863, 1982)
5' sense
3' antisense
IL-4 (PNAS 83:5894—5898, 1986)
5' sense
3' antisense
JL-7 (PNAS 86:302—306, 1989)
5' sense
3' antisense
TGF-13, (Nature 316:701—705, 1985)
5' sense
3' antisense
j3-actin (PNAS 82:6133—6137, 1985)
5' sense
3' antisense
TAA GGG TTA CCT GGG TTG CCA A
CAC TCA TGG CTT TGT AGA TGC C
CCT CTG GAG GAA GTG CTA AA
ATG GTT GCT GTC TCA TCA GC
GCA GGT CAT TCA GAT GTA GC
TTC CTT GAT GGT CTC CAC AC
TTC TAC AGC CAC CAT GAG AAG
CAG CTC GAA CAC TTT GAA TAT
TGA AGG TAA AGA TGG CAA ACA
GAG CAG CAC GGA ATA AAA ACA
CTG CGG ATC TCT GTG TCA TT
CTC AGA GTG TTG CTA TGG TG
GGT CAC CCA CAC TGT GCC CAT
GGA TGC CAC AGG ACT CCA TGC
(252—273) 257bp
(487—508)
(3113—3132) 149bp
(5087—5106)
(1831—1850) 177bp
(2083—2102)
(298—318) 227bp
(504—524)
(471—491) l7Obp
(620—640)
(2154—2173) 246bp
(2380—2399)
(2139—2159) 350bp
(2563—2583)
Fig. 1. Histopathological diagnosis of renal
allograft biopsy specimens. The histological
diagnosis of renal allograft biopsy samples were
based on Banif working classification criteria
for diagnosing kidney transplant pathology [15].
Abbreviations are: AR, acute rejection; CsA/
ATN, CsA nephrotoxicity and/or acute tubular
necrosis; CAN, chronic allograft nephropathy;
Other, non-specific changes or recurrent renal
disease. The numbers (N) represent the number
of tissue samples with the primary histological
diagnosis.
eosinophilic inclusions, microcalcification, hyaline arteriolar
thickening and striped or patch fibrosis were considered as
features of CsA nephrotoxicity [151.
Molecular studies of renal allograft biopsy specimens
RNA isolation. Portions of renal biopsy tissue were snap-frozen
in liquid nitrogen and stored at —70°C for later RNA extraction.
The renal tissue was homogenized with a tissue tearer in 4 M
guanidium thiocyanate solution. RNA extraction was performed
as described [161 and quantified by spectrophotometry.
Reverse transcription-assisted PCR. Reverse transcription-PCR
was performed as described [161. Table 1 lists the sequence and
location of the oligonucleotide primer pairs used to amplify
cytokine mRNA. The predicted size of the PCR products is also
provided. The primers were generally designed to flank an intron
site in the target sequence. This primer design permits prompt
detection of any genomic contamination of the RNA preparation
from the renal biopsy specimens. Also, in each instance, f3-actin
mRNA was amplified as an internal control for RT-PCR [161.
Results
Histological diagnosis of renal allograft biopsies
Figure 1 illustrates the number of biopsies classified on the
basis of Banif working classification criteria [15]. Among the 98
biopsies, 63 were diagnosed as acute rejection; 20 as chronic
allograft nephropathy; 6, consistent with CsA nephrotoxicity
and/or ATN. Nine of the biopsies revealed non-specific morpho-
logical alterations or recurrent renal disease (IgA nephropathy =
2; DM = 2; FSGS = 1).
Intragraft IL-b mRNA expression and acute rejection
Forty-three of the 98 biopsy specimens were positive for IL-b
mRNA. Among the 43 biopsies that were positive for IL-b
mRNA, 36 displayed histological features of acute rejection;
among the 55 samples that were negative for IL-b mRNA, 27
displayed features of acute rejection. The association between
intragraft IL-b mRNA expression and acute rejection was signif-
icant at the P = 0.0005 level by Fischer's exact test (Table 2).
With regard to acute rejection, the sensitivity of intragraft IL-b
mRNA expression was 0.57; specificity was 0.80; and the positive
and negative predictive values were 0.84 and 0.51, respectively.
IL-2 mRNA and acute rejection
Eleven of the renal allograft biopsy specimens were positive for
IL-2 mRNA; among the 11 that were positive, all exhibited
histological features of acute rejection. However, among the 87
that were negative for intragraft IL-2 mRNA expression, 52 were
positive for acute rejection. The association between intragraft
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Table 2. Correlation between intragraft cytokine mRNA expression
and acute rejection
Acute
Intragraft
mRNA +
rejection
pa
IL-b mRNA + (43) 36 7
IL-lO mRNA — (55) 27 28 0.0005
IL-2 mRNA + (11) 11 0
IL-2 mRNA — (87) 52 35 0.015
IFN-y mRNA + (47) 34 13
IFN-y mRNA — (44) 25 19 0.131
TGF-131 mRNA + (57) 36 21
TGF-f31 mRNA — (40) 26 14 0.512
IL-4 mRNA + (2) 2 0
IL-4 mRNA — (55) 35 20 0.536
IL-7 mRNA + (45) 31 14
IL-7 mRNA — (12) 6 6 0.309
() is the number of samples positive or negative for intragraft mRNA
expression.aPvalue determined by Fischer's exact test
IL-2 mRNA expression and acute rejection was significant at P =
0.015 level (Table 2).
With regard to acute rejection, the sensitivity of intragraft IL-2
mRNA expression was 0.17; specificity was 1.0; and the positive
and negative predictive values were 1.0 and 0.40, respectively.
mRNA encoding IFN-y, IL-4, IL-7, or TGF-131 and acute
rejection
In contrast to the significant association between acute rejec-
tion and IL-lO mRNA as well as IL-2 mRNA expression, intra-
graft expression of mRNA encoding IFN-y (number of biopsies =
91), TGF-p1 (N = 97), IL-4 (N = 57) or IL-7 (N = 57) was not
a correlate of acute rejection (Table 2).
Coexpression of IL-b mRNA and IFN-y mRNA
IL-b was initially characterized as a secretory product of
murine CD4+ T helper type II clones that inhibits IFN-y produc-
tion by CD4+ T helper type I clones. In contrast to this in vitro
observation, IL-b and IFN-y were coexpressed in 32 renal
allograft biopsies. The significant association (P = 0.00007)
between IL-b and IFN-y expression and that between IL-b and
TGF-131 (P = 0.006) are summarized in Table 3. It is also shown
in Table 3 that IL-b expression does not prevent intrarenal
expression of mRNA encoding IL-2 or IL-7.
Discussion
The cytokine synthesis inhibitory activity of IL-b and its ability
to constrain APC function of monocytes and the functional
programs of T cells have led to the consideration that IL-b might
function in vivo as an immunosuppressive cytokine. Our demon-
stration that intragraft IL-b mRNA expression is a positive
correlate of acute rejection, however, challenges this notion and
advances instead the hypothesis that this multifunctional cytokine
might function in vivo as an immunostimulatory polypeptide.
Data generated with IL-b transgenic animals support our
postulate that IL-b might function in vivo as an immunostimu-
latory polypeptide. Wogensen, Huang and Sarvetnick [17] have
shown that transgenic expression of IL-b in pancreatic islet f3
cells is associated with a prominent inflammatory cell infiltration,
and Wogensen, Lee and Sarvetnick [19] have demonstrated that
Table 3. Coexpression of IL-lO mRNA with mRNA encoding IFN-y,
TGF-131, IL-2, IL-4 or IL-7
Intragraft
mRNA
IL-lO mRNA
+ - pa
IFN-y mRNA + (46) 32 14
IFN-y mRNA — (44) 12 32 0.00007
TGF-131 mRNA + (57) 32 25
TGF-/31 mRNA — (40) 11 29 0.006
IL-2 mTNA + (11) 8 3
LL-2 mRNA — (87) 35 52 0.547
IL-4 mRNA + (2) 2 0
IL-4 mRNA — (55) 23 32 0.187
IL-7 mRNA + (45) 20 25
IL-7 mRNA — (12) 4 8 0.532
() is the number of samples positive or negative for intragraft mRNA
expression.
aP value determined by Fischer's exact test
the expression of the transgene does not protect the islets from
allograft rejection. A lack of protection from auto-immune dia-
betogenic mechanisms has also been reported with the IL-b
transgenic NOD mice. Indeed, transgenic expression of IL-b in
the pancreatic 13 cells or a cells has been shown to accelerate the
development of diabetes in the NOD mice [19, 20]. Additional
data that support an immunostimulatory rather than an immuno-
suppressive role for IL-b include: (a) IL-tO transfected into
Chinese hamster ovary (CHO) cells prevents the tumorigenicity of
CHO cells [21]; (b) IL-b induces differentiation of precursors of
cytotoxic T cells [22] and enhances Fe receptor dependent cyto-
toxic activity of monocytes [23]) and provides help to B cells for
antibody synthesis [24]); and (c) intragraft IL-b mRNA expres-
sion is significantly higher in the rejecting murine pancreatic islet
allografts as compared to the well-functioning allografts.
Results from the current investigation also demonstrate that
IL-b does not prevent in vivo expression of IFN-y, TGF-131, IL-2
or IL-7. Our in vivo observations, unanticipated in light of the
earlier in vitro data that IL-tO inhibits the induced expression of
IL-2 and IFN-y [2—6], emphasize the complexity of in vivo
immunoregulatory circuits and are reminiscent of the coexpres-
sion of IFN-y and IL-b following experimental brucella abortus
infection [25]. Moreover, since IL-b down-regulates T cell func-
tions when monocytes function as APCs but not when dendritic
cells function as APCs [26], our data also suggest the participation
in vivo of cell types in addition to monocytes as antigen presenting
cells.
Our investigation, comprised of 98 renal allograft biopsies, has
identified several biological features of potential clinical value.
For example, in view of the strong association between acute
rejection and intragraft expression of IL-b mRNA, future anti-
rejection strategies might include approaches to constrain the
expression of this multifunctional cytokine. On the other hand,
since IL-2 mRNA was detected in only 11 of 63 acute rejection
biopsy specimens and IFNy mRNA was not a correlate of
rejection, current treatment protocols appear to be quite effective
in preventing IL-2 and/or IFN-y dependent rejection.
We anticipated a negative association between TGF-f3b expres-
sion and acute rejection (since TGF-f31 is an inhibitor of T cell
responses), and a positive association between IL-7 expression
and rejection (since IL-7 is a T cell growth factor, and its
expression is not prevented by CsA [27]). IL-7 was indeed a highly
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sensitive index (0.84) of rejection, but was not a specific one
(0.30). TGF-f31 expression might have been confounded by the
fact that the graft recipients were treated with CsA, and TGF-131
expression is stimulated by CsA [161. In this regard, whereas
intragraft TGFI31 mRNA was not a correlate of acute rejection,
this fibrogenic cytokine was significantly associated with histologic
features of chronic allograft nephropathy (V.K. Sharma et a!,
manuscript in preparation).
Of the cytokines evaluated, intragraft expression of IL-4 was the
least common; IL-4 mRNA was detected in only 2 of 57 renal
allograft biopsies. This lack of detection is intriguing since IL-4
has been implicated in tolerance observed in experimental models
of transplantation [14], and authentic tolerance in the clinical
setting is quite uncommon.
In summary, cytokine mRNA phenotyping of RNA isolated
from 98 human renal allograft biopsy specimens has identified, for
the first time, a significant and positive correlation between
intragraft IL-b mRNA expression, and histologically confirmed
acute renal allograft rejection. This provocative observation chal-
lenges the current perception of IL-b as an immunosuppressant
and emphasizes the need for additional in vivo studies to further
characterize the role of this multifunctional polypeptide and to
critically evaluate the role of types I and II cytokines in the clinic.
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